S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Next Science Stock Price, News & Analysis (ASX:NXS)

A$2.75
-0.07 (-2.48 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
A$2.75
Now: A$2.75
A$2.82
50-Day Range N/A
52-Week Range
A$1.24
Now: A$2.75
A$4.73
Volume50,407 shs
Average VolumeN/A
Market Capitalization$490.92 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Next Science Limited, a medical technology company, develops and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria. The company develops its products using its Xbio Technology platform. It offers SurgX, an innovative surgical gel designed to reduce superficial surgical site infections and protect wound tissue to facilitate natural healing; and Bactisure, a surgical lavage that is used to remove debris, including microorganisms from wounds. The company also provides TorrentX, an antimicrobial wound wash; and BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment. In addition, it is developing acne gel; middle ear wash for use in patients with chronic ear infections; minimally invasive surgical lavage to replace a saline wound lavage; nasal packing stent for use in recovery from nasal surgery; adhesion barrier that is implanted in surgery field to prevent internal adhesion; and soft coating for implants. Further, the company develops tropical treatments for school sores, infected atopic dermatitis, and fungal nails; tropical preventative treatment for keloid scarring; and products for bacterial vaginosis, as well as over the counter products, such as mouthwash. Next Science Limited was founded in 2012 and is headquartered in Sydney, Australia.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 8607 5124

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.46 million
Cash FlowA$0.12 per share
Book ValueA$0.14 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$490.92 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NXS News and Ratings via Email

Sign-up to receive the latest news and ratings for NXS and its competitors with MarketBeat's FREE daily newsletter.


Next Science (ASX:NXS) Frequently Asked Questions

What is Next Science's stock symbol?

Next Science trades on the ASX under the ticker symbol "NXS."

Has Next Science been receiving favorable news coverage?

Press coverage about NXS stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Next Science earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Next Science.

Who are some of Next Science's key competitors?

Who are Next Science's key executives?

Next Science's management team includes the folowing people:
  • Ms. Judith Mitchell M.B.A., MD, CEO & Director
  • Dr. Matthew Myntti, Founder & CTO
  • Ms. Jacqueline Butler CA (ICAEW), Chief Financial Officer
  • Mr. Jon Swanson, Chief Operating Officer
  • Mr. Don Ayers, VP of Sales & Marketing

What is Next Science's stock price today?

One share of NXS stock can currently be purchased for approximately A$2.75.

How big of a company is Next Science?

Next Science has a market capitalization of $490.92 million and generates $4.46 million in revenue each year. View Additional Information About Next Science.

What is Next Science's official website?

The official website for Next Science is http://www.nextscience.com/.

How can I contact Next Science?

The company can be reached via phone at 61 2 8607 5124.


MarketBeat Community Rating for Next Science (ASX NXS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  2 (Vote Outperform)
Underperform Votes:  2 (Vote Underperform)
Total Votes:  4
MarketBeat's community ratings are surveys of what our community members think about Next Science and other stocks. Vote "Outperform" if you believe NXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel